The Acute Ischemic Stroke drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Ischemic Stroke. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued products.
GlobalData tracks 106 drugs in development for Acute Ischemic Stroke by 94 companies/universities/institutes. The top development phase for Acute Ischemic Stroke is phase i with 30 drugs in that stage. The Acute Ischemic Stroke pipeline has 106 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Acute Ischemic Stroke pipeline products market are: Simcere Pharmaceutical Group, Saillant Therapeutics and Suzhou Pharmavan Cancer Research Center.
The key targets in the Acute Ischemic Stroke pipeline products market include Free Radical, Plasminogen (Plasmin or PLG or EC 3.4.21.7), and Tissue Type Plasminogen Activator (t Plasminogen Activator or Alteplase or Reteplase or Plasminogen/Activator Kringle or PLAT or EC 3.4.21.68).
The key mechanisms of action in the Acute Ischemic Stroke pipeline product include Free Radical Scavenger with seven drugs in Phase III. The Acute Ischemic Stroke pipeline products include 14 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Acute Ischemic Stroke pipeline products market including Small Molecule, and Monoclonal Antibody.
Acute Ischemic Stroke overview
An acute ischemic stroke occurs when a clot blocks a brain blood vessel, depriving it of oxygen. Symptoms, like numbness, confusion, or difficulty speaking, arise suddenly. Immediate medical attention is crucial. Treatment focuses on restoring blood flow, often with clot-dissolving drugs or a thrombectomy. Recovery varies; rehabilitation helps regain lost abilities. Lifestyle changes and medication may prevent future strokes. Early recognition and swift intervention significantly improve recovery chances, emphasizing the importance of prompt action at the first signs of a stroke.
For a complete picture of Acute Ischemic Stroke’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
